Yes. A nested trial studied participants with knee osteoarthritis, and results pointed to reduced knee pain alongside weight loss, likely tied to less joint strain and lower inflammation

Yes. Another nested trial included participants with moderate to severe obstructive sleep apnea, and the drug showed improvement in that condition too consistent with how significant weight loss often eases sleep apnea severity.

Yes. Retatrutide showed significant improvements in glycaemic control and bodyweight reduction as a monotherapy in adults with type 2 diabetes that is inadequately controlled with diet and exercise alone

Yes. Significant improvements were observed in blood pressure, lipid (cholesterol) profiles, and liver fat content among trial participants.

One expert who has consulted for Eli Lilly described retatrutide as the GLP-1-class medicine viewed as the most potent, with the greatest weight loss potential, since it acts on an extra hormone pathway that those drugs don’t target. That said, no direct head-to-head trial has compared them yet.

Trial results have been described as historic. Participants using the highest doses achieved weight loss described as putting retatrutide essentially on par with bariatric surgery for some participants who tolerated dose escalation to the maximum level.

No. Eli Lilly is expected to submit its FDA application later in 2026, with approval potentially following in 2027 and commercial availability after that. It isn’t a legally available, approved prescription drug today.

This is one of its most promising benefits. The glucagon receptor component is believed to help the liver burn stored fat more effectively, a mechanism not present in GLP-1-only or dual GIP/GLP-1 drugs like semaglutide and tirzepatide. Trials have shown meaningful improvement in liver fat content, which matters for conditions like MASLD (fatty liver disease)

The trial reported an adverse event profile consistent with other drugs in its class, meaning GI-related side effects (nausea, vomiting, diarrhea) similar to other GLP-1 drugs are expected. Longer-term safety data are still being collected as more trials report through 2026.

It’s an investigational injectable medication known as a “triple agonist” — it targets three hormone receptors (GLP-1, GIP, and glucagon) instead of just one or two, unlike earlier drugs such as semaglutide (Wegovy) or tirzepatide (Zepbound). It’s developed by Eli Lilly and is not yet approved by the FDA — it remains investigational.